Detaljert guide kommer snart
Vi jobber med en omfattende veiledning for Cockcroft-Gault Creatinine Clearance. Kom tilbake snart for trinnvise forklaringer, formler, eksempler fra virkeligheten og eksperttips.
The Cockcroft-Gault equation estimates creatinine clearance (CrCl) as a surrogate for glomerular filtration rate, using age, weight, sex, and serum creatinine. Published in 1976 by Donald Cockcroft and Henry Gault, it was derived from 249 male inpatients and remains one of the most widely used pharmacokinetic tools in medicine. Unlike CKD-EPI, which estimates GFR normalised to body surface area, Cockcroft-Gault provides an absolute creatinine clearance in mL/min that is not BSA-adjusted, making it particularly relevant for drug dosing. The majority of renally cleared drugs — including direct oral anticoagulants (NOACs, specifically rivaroxaban, apixaban, dabigatran), aminoglycosides, vancomycin, metformin, lithium, and low-molecular-weight heparins — have dose adjustment thresholds based on Cockcroft-Gault creatinine clearance from their original pharmacokinetic studies. This means that even in 2024, when CKD-EPI is the preferred equation for CKD staging, Cockcroft-Gault remains mandatory for many drug prescribing decisions. Understanding when to use each equation, and how to adjust for body weight in obese patients, is an essential clinical skill that prevents both underdosing and dangerous drug accumulation. Developed in 1976 by Cockcroft and Gault from a population of 249 hospitalised men, this equation remains the most widely used formula for drug dosing calculations despite being over 45 years old. It estimates creatinine clearance (CrCl) rather than GFR, and while it has important limitations — particularly in obesity, elderly patients, and those with rapidly changing renal function — it remains the basis for dosing decisions in critical drug categories including NOACs (apixaban, rivaroxaban, dabigatran, edoxaban), low molecular weight heparins, aminoglycosides, vancomycin, metformin, and lithium. Regulatory agencies including the FDA and EMA continue to reference Cockcroft-Gault for labelling and dosing recommendations, making it indispensable in clinical pharmacology and hospital prescribing.
CrCl (mL/min) = [(140 − Age) × Weight × F] / (72 × Scr); F = 1.0 (male), 0.85 (female). SI: CrCl = [(140 − Age) × Weight × F] / (0.814 × Scr µmol/L)
- 1Obtain inputs: age (years), actual body weight in kg, sex, and serum creatinine in mg/dL (or µmol/L for SI).
- 2Calculate the numerator: (140 − age) × weight × sex factor. The sex factor is 1.0 for males and 0.85 for females (reflecting lower average muscle mass).
- 3Divide by the denominator: 72 × serum creatinine (mg/dL). For SI units, use 0.814 × creatinine (µmol/L).
- 4In obese patients, use ideal body weight (IBW) or adjusted body weight (ABW) rather than actual body weight to avoid overestimating CrCl. IBW (male) = 50 + 2.3 × (height in inches − 60); IBW (female) = 45.5 + 2.3 × (height in inches − 60). ABW = IBW + 0.4 × (Actual BW − IBW).
- 5In underweight patients (actual BW < IBW), use actual body weight.
- 6Round the final result to the nearest whole number. CrCl >120 mL/min may indicate hyperfiltration or muscle mass extremes — interpret with clinical context.
- 7Map the CrCl to drug-specific dose adjustment thresholds as stated in the drug's prescribing information.
Dose-reduce aminoglycosides; check extended-interval dosing guidelines
Numerator = (140 − 60) × 75 × 1.0 = 6000. Denominator = 72 × 1.2 = 86.4. CrCl = 6000/86.4 = 69.4 mL/min. For gentamicin, CrCl 40–80 warrants modified interval.
Meets two of three criteria for apixaban dose reduction (age ≥80, weight ≤60 kg, creatinine ≥1.5); full standard dose likely appropriate — verify against full criteria
Numerator = (140 − 78) × 58 × 0.85 = 3057.4. Denominator = 72 × 1.0 = 72. CrCl = 42.5 mL/min. Patient meets weight criterion for 2.5 mg BD apixaban if also age ≥80 or Cr ≥1.5.
Using actual body weight of 130 kg would overestimate CrCl to ~168 mL/min — clinically dangerous for drug dosing
IBW = 50 + 2.3 × (69 − 60) = 50 + 20.7 = 70.7 kg. ABW = 70.7 + 0.4 × (130 − 70.7) = 70.7 + 23.7 = 94.4 kg. Using ABW: (140−50) × 94.4 × 1.0 / (72 × 1.0) = 8496/72 = 118 mL/min.
Metformin is contraindicated below CrCl 30 mL/min — discontinue to avoid lactic acidosis risk
Numerator = (140 − 82) × 52 × 0.85 = 2563.6. Denominator = 72 × 1.3 = 93.6. CrCl = 27.4 mL/min. Below the metformin contraindication threshold of 30 mL/min (UK) or 30 mL/min (FDA).
Dose adjustment for dabigatran, rivaroxaban, and apixaban in atrial fibrillation and VTE treatment, enabling practitioners to make well-informed quantitative decisions based on validated computational methods and industry-standard approaches, which requires precise quantitative analysis to support evidence-based decisions, strategic resource allocation, and performance optimization across diverse organizational contexts and professional disciplines
Vancomycin AUC-guided dosing and interval adjustment for serious gram-positive infections, helping analysts produce accurate results that support strategic planning, resource allocation, and performance benchmarking across organizations, where accurate numerical computation is essential for producing reliable outputs that inform planning, evaluation, and continuous improvement processes in both corporate and individual settings
Metformin safety assessment — contraindicated below CrCl 30 mL/min to prevent lactic acidosis, allowing professionals to quantify outcomes systematically and compare scenarios using reliable mathematical frameworks and established formulas, demanding systematic calculation approaches that translate raw input data into actionable insights for stakeholders who depend on quantitative rigor in their daily professional activities
Enoxaparin dose reduction in patients with renal impairment (CrCl <30 mL/min requires dose halving), supporting data-driven evaluation processes where numerical precision is essential for compliance, reporting, and optimization objectives, necessitating robust computational methods that deliver consistent and verifiable results suitable for reporting, auditing, and long-term trend analysis in professional environments
Aminoglycoside dosing interval extension and therapeutic drug monitoring in serious infections, which requires precise quantitative analysis to support evidence-based decisions, strategic resource allocation, and performance optimization across diverse organizational contexts and professional disciplines
Severe obesity (BMI >40)
In morbid obesity, neither actual body weight nor IBW accurately represents creatinine-generating muscle mass. Adjusted body weight (ABW = IBW + 0.4 × [ABW − IBW]) is the recommended compromise. Some institutions use lean body mass equations. Using actual body weight in severe obesity can overestimate CrCl by 50–100%, with dangerous implications for narrow-therapeutic-index drugs.
Amputation and limb loss
Standard weight-based equations overestimate CrCl in amputees since actual body weight includes functional limbs. Corrections should be applied: a below-knee amputation reduces weight by approximately 5.9%, above-knee by 11%, and forearm by 2.3%. Failure to correct can lead to underdosing in the presence of apparent 'adequate' CrCl.
Rapidly rising creatinine
When creatinine is rising acutely (AKI), the formula overestimates CrCl because it uses the current creatinine value while true GFR is already much lower. Some clinicians use the average of the previous and current creatinine, though this is not formally validated. In AKI, direct clinical assessment and urine output monitoring are more reliable.
Muscle-wasting conditions
Patients with cachexia, motor neurone disease, severe sarcopenia, or spinal cord injury have disproportionately low muscle mass for their weight. Serum creatinine may be falsely low (0.4–0.6 mg/dL), leading Cockcroft-Gault to report a deceptively high CrCl. Cystatin C or 24-hour urine creatinine clearance should supplement estimation in these cases.
| Drug | CrCl Threshold | Action |
|---|---|---|
| Metformin | < 30 mL/min | Contraindicated (lactic acidosis risk) |
| Dabigatran | < 30 mL/min | Contraindicated; caution 30–50 |
| Rivaroxaban (VTE) | < 30 mL/min | Avoid; dose-reduce 15–49 |
| Apixaban | < 15 mL/min | Not recommended |
| Enoxaparin | < 30 mL/min | Dose-reduce (0.5 mg/kg OD) |
| Vancomycin | All levels | AUC-guided dosing; monitor levels |
| Aminoglycosides | < 60 mL/min | Extend dosing interval; monitor troughs |
| Lithium | < 50 mL/min | Reduce dose; increase monitoring frequency |
Why do I use Cockcroft-Gault instead of CKD-EPI for drug dosing?
Drug dose adjustment thresholds were established using Cockcroft-Gault in original pharmacokinetic studies conducted before CKD-EPI existed. Regulatory bodies (FDA, EMA) approved doses based on these thresholds. Substituting CKD-EPI can lead to inappropriate dosing, particularly in elderly and obese patients where the two equations may diverge significantly. Always use the equation specified in the drug's prescribing information.
What weight should I use in obese patients?
In patients where actual body weight exceeds ideal body weight by more than 20%, use adjusted body weight (ABW = IBW + 0.4 × [Actual − IBW]). Using actual body weight overestimates CrCl because excess adipose tissue does not generate proportionally more creatinine. The 0.4 correction factor reflects that approximately 40% of excess body weight above IBW contributes to creatinine production.
Is Cockcroft-Gault accurate in the elderly?
Cockcroft-Gault tends to overestimate CrCl in elderly patients, particularly those with sarcopenia (muscle wasting), because the formula uses weight without independently accounting for muscle mass. A frail 80-year-old with a low serum creatinine due to little muscle may have a CrCl that appears reassuringly normal yet masks substantially impaired kidney function. Clinical judgement and, where available, cystatin C measurement improve accuracy in this population.
Does Cockcroft-Gault need to be adjusted for body surface area?
The raw Cockcroft-Gault CrCl is not normalised to BSA. If you wish to compare it to eGFR (which is normalised to 1.73 m² BSA), you can apply the correction: BSA-adjusted CrCl = CrCl × 1.73 / patient BSA. However, for drug dosing, the unadjusted (non-BSA-corrected) value is what was used in pharmacokinetic studies and is the appropriate value to use.
What is the female correction factor of 0.85?
The 0.85 factor reflects that women on average have approximately 15% less muscle mass than men of the same weight and age, and therefore produce less creatinine. Since creatinine clearance is being used as a proxy for GFR, and creatinine production is lower in women, a downward correction prevents overestimation of kidney function.
Can Cockcroft-Gault be used in acute kidney injury?
No. Like all creatinine-based GFR estimates, Cockcroft-Gault assumes steady-state creatinine. In AKI, creatinine is rapidly rising and does not reflect true GFR. A creatinine of 1.5 mg/dL in a patient who was previously 0.8 mg/dL represents far worse function than the Cockcroft-Gault output suggests. Use clinical assessment, urine output, and AKI staging criteria in the acute setting.
Which drugs most critically require Cockcroft-Gault dosing?
The drugs where Cockcroft-Gault errors are most consequential include: dabigatran (risk of major bleeding at CrCl <30, contraindicated <15), rivaroxaban (dose reduction at CrCl 15–49 for VTE treatment), vancomycin (AUC-guided dosing requires accurate CrCl), aminoglycosides (toxicity risk with reduced clearance), lithium (narrow therapeutic index), and low-molecular-weight heparins such as enoxaparin (dose-reduce at CrCl <30).
What happens in pregnancy with Cockcroft-Gault?
Pregnancy increases renal plasma flow and GFR by 40–65%. Serum creatinine falls to 0.4–0.6 mg/dL in a normal pregnancy. Cockcroft-Gault is not validated in pregnancy, and the rapidly changing physiology, expanded plasma volume, and altered protein binding make standard dose adjustment equations unreliable. Specialist obstetric pharmacy input is recommended for renally cleared drugs in pregnancy.
Pro Tips
In elderly women with low serum creatinine (e.g., 0.6 mg/dL), the Cockcroft-Gault formula may produce a paradoxically high-appearing CrCl due to very low creatinine in the denominator. Some guidelines recommend a minimum creatinine floor of 0.8 mg/dL for elderly women to avoid overestimating kidney function, though this is not universally adopted.
Visste du?
The Cockcroft-Gault equation was derived from just 249 male inpatients at a single Canadian hospital in 1973–1974, published in 1976. Despite being based exclusively on male patients, the female correction factor of 0.85 was added empirically — and this simple formula has been used to guide billions of drug prescribing decisions for nearly 50 years.
Referanser
- ›Cockcroft DW, Gault MH — Prediction of creatinine clearance from serum creatinine (Nephron 1976)
- ›Kidney Disease: Improving Global Outcomes (KDIGO) — CKD and Drug Dosing
- ›EMA — Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function
- ›Winter MA et al. — Role of renal function assessment in drug therapy (Pharmacotherapy 2006)
- ›NHS — Renal drug dosing guidance